CA
CYTK icon

Clearstead Advisors’s Cytokinetics CYTK Stock Holding History

Clearstead Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.95K Buy
105
+5
+5% +$359 ﹤0.01% 2013
2026
Q1 		$6.59K Sell
100
-570
-85% -$36.2K ﹤0.01% 1690
2025
Q4 		$42.6K Buy
670
+330
+97% +$20.5K ﹤0.01% 1470
2025
Q3 		$18.7K Hold
340
– – ﹤0.01% 1669
2025
Q2 		$11.2K Buy
340
+327
+2,515% +$11.4K ﹤0.01% 1849
2025
Q1 		$523 Buy
+13
New +$597 ﹤0.01% 2066
2024
Q4 		– Sell
-584
Closed -$30.8K – 2114
2024
Q3 		$30.8K Buy
584
+185
+46% +$10.3K ﹤0.01% 1315
2024
Q2 		$21.6K Buy
399
+64
+19% +$3.86K ﹤0.01% 1358
2024
Q1 		$19.4K Buy
+335
New +$25.9K ﹤0.01% 950

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's CYTK Position: Q2 2026 in Review

Clearstead Advisors increased its Cytokinetics (CYTK) stake by 5% in Q2 2026, buying an estimated $359 and bringing the position to 105 shares worth $8.95K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Clearstead Advisors first reported a position in CYTK in Q1 2024 and has held it in 9 quarters since. The position peaked at $42.6K in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Clearstead Advisors held 105 shares of Cytokinetics worth $8.95K as of Q2 2026.
  • Clearstead Advisors bought 5 Cytokinetics shares in Q2 2026, an estimated $359.
  • Cytokinetics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2013 holding.
  • Clearstead Advisors first reported a position in Cytokinetics in Q1 2024 and has held it in 9 quarters since.
  • Clearstead Advisors's Cytokinetics position peaked at $42.6K in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.